Nabriva Therapeutics Inc., of Dublin, said it earned a $5 million milestone payment under its agreement with Sinovant Sciences Ltd., of Shanghai, related to the U.S. regulatory approval of Xenleta (lefamulin). Sinovant, which has an exclusive license to develop and commercialize lefamulin in the greater China region, is set to start a clinical trial in China in the fourth quarter.